Holen Sie sich die Stockscreener-App
35.01
0.46%
0.16
Handel nachbörslich:
35.01
Schlusskurs vom Vortag:
$34.85
Offen:
$34.89
24-Stunden-Volumen:
85,169
Relative Volume:
0.68
Marktkapitalisierung:
$549.47M
Einnahmen:
$138.20M
Nettoeinkommen (Verlust:
$5.52M
KGV:
92.13
EPS:
0.38
Netto-Cashflow:
$9.86M
1W Leistung:
+2.67%
1M Leistung:
-8.23%
6M Leistung:
-11.84%
1J Leistung:
+6.77%
1-Tages-Spanne:
$34.76
$35.15
1-Wochen-Bereich:
$33.98
$35.15
52-Wochen-Spanne:
$25.17
$42.44
Surmodics Inc Stock (SRDX) Company Profile
Firmenname
Surmodics Inc
Sektor
Branche
Telefon
(952) 500-7000
Adresse
9924 W 74TH ST, EDEN PRAIRIE, MN
Vergleichen Sie SRDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
35.01 | 549.47M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
134.95 | 234.06B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.39 | 154.06B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
387.92 | 148.02B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.17 | 115.71B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.76 | 42.91B | 5.72B | 4.17B | 490.10M | 6.97 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-06-13 | Hochstufung | Needham | Hold → Buy |
| 2023-02-13 | Herabstufung | Needham | Buy → Hold |
| 2020-07-23 | Hochstufung | Needham | Hold → Buy |
| 2019-12-11 | Herabstufung | Needham | Buy → Hold |
| 2019-11-01 | Herabstufung | Lake Street | Buy → Hold |
| 2019-08-01 | Bestätigt | Needham | Buy |
| 2019-05-02 | Bestätigt | Lake Street | Buy |
| 2019-05-02 | Bestätigt | Needham | Buy |
| 2019-02-21 | Bestätigt | Needham | Buy |
| 2018-05-16 | Bestätigt | Needham | Buy |
| 2018-03-01 | Hochstufung | Sidoti | Neutral → Buy |
| 2018-02-28 | Bestätigt | Lake Street | Buy |
| 2018-02-28 | Eingeleitet | Needham | Buy |
| 2017-07-14 | Eingeleitet | Lake Street | Buy |
| 2016-11-21 | Herabstufung | Barrington Research | Outperform → Mkt Perform |
| 2016-10-06 | Herabstufung | Sidoti | Buy → Neutral |
| 2016-05-03 | Bestätigt | Barrington Research | Outperform |
| 2015-08-06 | Bestätigt | Barrington Research | Outperform |
| 2015-03-27 | Eingeleitet | Dougherty & Company | Buy |
| 2014-02-25 | Eingeleitet | Laidlaw | Buy |
| 2013-08-01 | Hochstufung | Feltl & Co. | Buy → Strong Buy |
| 2012-11-12 | Bestätigt | Barrington Research | Outperform |
Alle ansehen
Surmodics Inc Aktie (SRDX) Neueste Nachrichten
What is Zacks Research’s Estimate for Surmodics Q2 Earnings? - Defense World
Q3 Earnings Forecast for Surmodics Issued By Zacks Research - Defense World
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
(SRDX) Technical Data - Stock Traders Daily
Surmodics shareholders approve key proposals at annual meeting - MSN
Surmodics shareholders approve key proposals at annual meeting By Investing.com - Investing.com Nigeria
Surmodics (NASDAQ:SRDX) Issues Quarterly Earnings Results - Armenian Reporter
Surmodics Q2 EPS Estimate Decreased by Barrington Research - MarketBeat
Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
Short Interest in Surmodics, Inc. (NASDAQ:SRDX) Increases By 33.0% - MarketBeat
Ratios in Focus: Analyzing Surmodics, Inc (SRDX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Surmodics' (SRDX) "Hold" Rating Reaffirmed at Needham & Company LLC - MarketBeat
Surmodics (NASDAQ:SRDX) Posts Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
What is Zacks Research's Estimate for Surmodics Q2 Earnings? - MarketBeat
SurModics (SRDX) Loses -13.87% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Revolutionary Blood Clot Treatment: Surmodics' New Pounce XL System Tackles Larger Arteries - StockTitan
Surmodics (NASDAQ:SRDX) Now Covered by StockNews.com - Defense World
Barrington Research Lowers Earnings Estimates for Surmodics - Defense World
Surmodics (SRDX) Expected to Announce Earnings on Thursday - MarketBeat
Surmodics (NASDAQ:SRDX) Trading Down 5.5%Time to Sell? - MarketBeat
Zacks Research Has Positive Outlook of Surmodics Q2 Earnings - Defense World
Surmodics Stock Down Despite Q1 Earnings Beat, Gross Margin Up - MSN
Zacks Research Increases Earnings Estimates for Surmodics - Defense World
SurModics: Fiscal Q1 Earnings Snapshot - CT Insider
Surmodics Reports Q1 Loss and Strategic Moves - TipRanks
SurModics (SRDX) Reports Q1 Loss, Misses Revenue Estimates - MSN
Compared to Estimates, SurModics (SRDX) Q1 Earnings: A Look at Key Metrics - Nasdaq
Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - BioSpace
Surmodics Earnings Analysis: Q1 Recap - Benzinga
Surmodics Inc. (SRDX) reports earnings - Quartz
Surmodics Inc Reports Q1 FY2025 EPS of $(0.26) and Revenue of $2 - GuruFocus.com
SurModics: Fiscal Q1 Earnings Snapshot -January 30, 2025 at 07:25 am EST - Marketscreener.com
Surmodics (SRDX) to Release Earnings on Thursday - Defense World
Here's Why You Should Add Surmodics Stock to Your Portfolio Now - MSN
Surmodics falls on report about FTC review of GTCR deal - Seeking Alpha
Surmodics (NASDAQ:SRDX) Coverage Initiated by Analysts at StockNews.com - Defense World
JPMorgan Chase & Co. Buys 27,960 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Finanzdaten der Surmodics Inc-Aktie (SRDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.10%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):